Key terms
About BIIB
Biogen, Inc. is a biopharmaceutical company, which engages in discovering, developing, and delivering therapies for neurological and neurodegenerative diseases. Its products include TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI and FAMPYRA for the treatment of MS, SPINRAZA for the treatment of SMA, ADUHELM for the treatment of Alzheimer's disease, and FUMADERM for the treatment of severe plaque psoriasis. The company was founded by Charles Weissmann, Heinz Schaller, Kenneth Murray, Walter Gilbert, and Phillip Allen Sharp in 1978 and is headquartered in Cambridge, MA.
Sector
Industry
Employees
Founded
Website
Key stock statistics
1-day range
52-week range
Market cap
P/E ratio
Next earnings date
Dividend yield
Ex-dividend date
Dividend pay date
Key terms
Ad Feedback
Smart score
Latest BIIB news
Yesterday
5:50am ET
Analysts Offer Insights on Healthcare Companies: Biogen (BIIB), Dexcom (DXCM) and Herbalife (HLF)
Yesterday
2:22am ET
Buy Rating Justified: Biogen’s Promising Drug Launches and Strategic Growth Initiatives
Yesterday
2:09am ET
Biogen’s Surpassing Performance and Positive Outlook Affirm Buy Rating
Yesterday
1:58am ET
Biogen’s Financial Upswing: Strong Q1 Performance and Market Penetration Justify Buy Rating
Apr 25
4:45pm ET
Biogen announces CHMP opinion recommending Tofidence
Apr 25
4:44pm ET
Biogen receives positive CHMP opinion for TOFIDENCE
Apr 25
2:16pm ET
Sage Therapeutics price target lowered to $18 from $22 at Truist
Apr 25
8:28am ET
Biogen price target raised to $215 from $213 at Wedbush
Apr 25
7:56am ET
Jefferies Keeps Their Buy Rating on Biogen (BIIB)
Apr 25
7:32am ET
Analysts’ Top Healthcare Picks: BioMarin Pharmaceutical (BMRN), Universal Health (UHS)
Apr 25
7:28am ET
Biogen price target lowered to $250 from $260 at BofA
Apr 25
7:10am ET
Truist Financial Reaffirms Their Buy Rating on Biogen (BIIB)
Apr 25
7:02am ET
Analysts Offer Insights on Healthcare Companies: Biogen (BIIB), Evolent Health (EVH) and BioMarin Pharmaceutical (BMRN)
Apr 25
6:58am ET
Biogen price target raised to $308 from $305 at Canaccord
Apr 25
5:40am ET
Analysts Offer Insights on Healthcare Companies: Thermo Fisher (TMO), Biogen (BIIB) and Molina Healthcare (MOH)
Apr 25
4:58am ET
Biogen price target lowered to $200 from $215 at Barclays
Apr 24
9:10am ET
Analysts Have Conflicting Sentiments on These Healthcare Companies: Humana (HUM), Boston Scientific (BSX) and Biogen (BIIB)
Apr 24
8:00am ET
Analysts Offer Insights on Healthcare Companies: Biogen (BIIB) and BioMarin Pharmaceutical (BMRN)
Apr 24
6:50am ET
Biogen backs FY24 adjusted EPS view of $15.00-$16.00, consensus $15.46
Apr 24
6:48am ET
Biogen reports Q1 adjusted EPS $3.67, consensus $3.44
Apr 24
5:42am ET
Analysts Offer Insights on Healthcare Companies: Day One Biopharmaceuticals (DAWN), Biogen (BIIB) and Neurocrine (NBIX)
Apr 24
5:28am ET
QQQ ETF Update, 4/24/2024
Apr 23
8:25pm ET
Notable companies reporting before tomorrow’s open
Apr 23
1:18pm ET
Notable companies reporting before tomorrow’s open
Apr 23
5:19am ET
QQQ ETF Update, 4/23/2024
Apr 22
8:28am ET
Piper Sandler Sticks to Its Buy Rating for Biogen (BIIB)
Apr 19
7:50am ET
Analysts Are Bullish on These Healthcare Stocks: Gilead Sciences (GILD), Biogen (BIIB)
Apr 19
7:43am ET
Biogen price target lowered to $270 from $290 at Oppenheimer
Apr 17
6:52am ET
QQQ ETF Update, 4/17/2024
Apr 15
6:29am ET
QQQ ETF Update, 4/15/2024
Apr 12
6:56am ET
Biogen price target lowered to $260 from $280 at BofA
Apr 12
5:34am ET
SPY ETF Update, 4/12/2024
No recent press releases are available for BIIB
BIIB Financials
Key terms
Ad Feedback
BIIB Forecasts
analyst rating
- buy
- hold
- sell
1-year stock price forecast
BIIB Competitors
$ Market cap
P/E ratio
$ Price
1d change
52-week range